In the sensitivity analysis , which excluded 48/379 trials ( 13 % ) , 26/190 ( 14 % ) and 22/189 ( 12 % ) , respectively , results were significant at three months ( relative risk 5.1 , 1.1 to 22.9 , P = 0.02 ) and at six months ( 4.1 , 1.3 to 10.6 , P = 0.001 ) .